JP4767542B2 - 男性更年期が原因の異常の予防および／または治療のためのカルニチンの使用 - Google Patents

男性更年期が原因の異常の予防および／または治療のためのカルニチンの使用 Download PDF

Info

Publication number
JP4767542B2
JP4767542B2 JP2004560181A JP2004560181A JP4767542B2 JP 4767542 B2 JP4767542 B2 JP 4767542B2 JP 2004560181 A JP2004560181 A JP 2004560181A JP 2004560181 A JP2004560181 A JP 2004560181A JP 4767542 B2 JP4767542 B2 JP 4767542B2
Authority
JP
Japan
Prior art keywords
carnitine
propionyl
acetyl
acid
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004560181A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006511531A (ja
JP2006511531A5 (enExample
Inventor
アレアルド・コヴェレッチ
ジョルジョ・カヴァッリーニ
ジュリオ・ビアジョッティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of JP2006511531A publication Critical patent/JP2006511531A/ja
Publication of JP2006511531A5 publication Critical patent/JP2006511531A5/ja
Application granted granted Critical
Publication of JP4767542B2 publication Critical patent/JP4767542B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2004560181A 2002-12-13 2003-11-20 男性更年期が原因の異常の予防および／または治療のためのカルニチンの使用 Expired - Fee Related JP4767542B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM2002A000620 2002-12-13
IT000620A ITRM20020620A1 (it) 2002-12-13 2002-12-13 Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.
PCT/IT2003/000757 WO2004054567A1 (en) 2002-12-13 2003-11-20 Use of carnitines for the prevention and/or treatment of disorders caused by the andropause

Publications (3)

Publication Number Publication Date
JP2006511531A JP2006511531A (ja) 2006-04-06
JP2006511531A5 JP2006511531A5 (enExample) 2007-01-11
JP4767542B2 true JP4767542B2 (ja) 2011-09-07

Family

ID=32587900

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004560181A Expired - Fee Related JP4767542B2 (ja) 2002-12-13 2003-11-20 男性更年期が原因の異常の予防および／または治療のためのカルニチンの使用

Country Status (17)

Country Link
US (1) US7956091B2 (enExample)
EP (1) EP1569635B1 (enExample)
JP (1) JP4767542B2 (enExample)
KR (1) KR101039818B1 (enExample)
AT (1) ATE422883T1 (enExample)
AU (1) AU2003288739A1 (enExample)
CA (1) CA2507429C (enExample)
CY (1) CY1109051T1 (enExample)
DE (1) DE60326262D1 (enExample)
DK (1) DK1569635T3 (enExample)
ES (1) ES2322455T3 (enExample)
IT (1) ITRM20020620A1 (enExample)
MX (1) MXPA05006072A (enExample)
PL (1) PL211032B1 (enExample)
PT (1) PT1569635E (enExample)
SI (1) SI1569635T1 (enExample)
WO (1) WO2004054567A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272812A1 (en) * 2002-02-07 2005-12-08 Pettegrew Jay W Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans
US7407778B2 (en) 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US7815894B2 (en) 2003-05-29 2010-10-19 Jay W. Pettegrew Compounds, compositions and methods for medical imaging of neuropsychiatric disorders
ITRM20040561A1 (it) 2004-11-11 2005-02-11 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile.
KR101460125B1 (ko) * 2013-02-05 2014-11-11 주식회사 바이오그랜드 루이보스 추출물을 유효성분으로 하는 남성 노화 및 갱년기 예방 및 개선용 조성물
WO2016167254A1 (ja) * 2015-04-17 2016-10-20 株式会社山田養蜂場本社 蜂の子を含有する滋養強壮剤

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55136223A (en) * 1979-02-12 1980-10-23 Cavazza Claudio Brain metabolism obstruction treating agent
JPS562945A (en) * 1979-04-23 1981-01-13 Sigma Tau Ind Farmaceuti Amides of acylcarnitine and their manufacture and use
JP2001518484A (ja) * 1997-10-03 2001-10-16 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ アルコール中毒者の禁断症状とアルコールに対する渇望を抑制するための、および、健康な人のアルコールの濫用を防ぐための組成物
JP2002522382A (ja) * 1998-08-03 2002-07-23 シグマ−タウ・ヘルスサイエンス・ソシエタ・ペル・アチオニ カルニチンおよびカロテノイドを含む抗酸化、抗増殖組成物
JP2002523435A (ja) * 1998-09-01 2002-07-30 シグマ−タウ・ヘルスサイエンス・ソシエタ・ペル・アチオニ アセチルＬ−カルニチンおよびα−リポ酸を含む抗酸化組成物
WO2002096411A1 (en) * 2001-05-29 2002-12-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia
JP2002542191A (ja) * 1999-04-16 2002-12-10 シグマ−タウ・ヘルスサイエンス・ソシエタ・ペル・アチオニ グルタチオンの吸収を増しかつその効果を補強するのに有用な、カルニチンおよびグルタチオン含有組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3830931A (en) * 1972-11-06 1974-08-20 Felice S De Carnitine and its use in the treatment of arrhythmia and impaired cardiac function
IT1157238B (it) * 1982-10-29 1987-02-11 Sigma Tau Ind Farmaceuti Impiego di 1-carnitina per migliorare i paramenti biochimici e comportamentali dell'eta' senile
EP0681839A3 (en) * 1994-05-12 1997-11-12 Hirohiko Kuratsune A pharmaceutical preparation comprising an acylcarnitine
IT1290801B1 (it) * 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
US6399116B1 (en) * 2000-04-28 2002-06-04 Rulin Xiu Rhodiola and used thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55136223A (en) * 1979-02-12 1980-10-23 Cavazza Claudio Brain metabolism obstruction treating agent
JPS562945A (en) * 1979-04-23 1981-01-13 Sigma Tau Ind Farmaceuti Amides of acylcarnitine and their manufacture and use
JPH03236318A (ja) * 1979-04-23 1991-10-22 Sigma Tau Ind Farmaceut Riunite Spa 抗うつ剤
JP2001518484A (ja) * 1997-10-03 2001-10-16 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ アルコール中毒者の禁断症状とアルコールに対する渇望を抑制するための、および、健康な人のアルコールの濫用を防ぐための組成物
JP2002522382A (ja) * 1998-08-03 2002-07-23 シグマ−タウ・ヘルスサイエンス・ソシエタ・ペル・アチオニ カルニチンおよびカロテノイドを含む抗酸化、抗増殖組成物
JP2002523435A (ja) * 1998-09-01 2002-07-30 シグマ−タウ・ヘルスサイエンス・ソシエタ・ペル・アチオニ アセチルＬ−カルニチンおよびα−リポ酸を含む抗酸化組成物
JP2002542191A (ja) * 1999-04-16 2002-12-10 シグマ−タウ・ヘルスサイエンス・ソシエタ・ペル・アチオニ グルタチオンの吸収を増しかつその効果を補強するのに有用な、カルニチンおよびグルタチオン含有組成物
WO2002096411A1 (en) * 2001-05-29 2002-12-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia

Also Published As

Publication number Publication date
EP1569635A1 (en) 2005-09-07
PL211032B1 (pl) 2012-04-30
DK1569635T3 (da) 2009-04-20
JP2006511531A (ja) 2006-04-06
AU2003288739A1 (en) 2004-07-09
KR101039818B1 (ko) 2011-06-09
SI1569635T1 (sl) 2009-06-30
DE60326262D1 (de) 2009-04-02
US20060135606A1 (en) 2006-06-22
CA2507429A1 (en) 2004-07-01
ATE422883T1 (de) 2009-03-15
EP1569635B1 (en) 2009-02-18
MXPA05006072A (es) 2005-09-30
US7956091B2 (en) 2011-06-07
ITRM20020620A1 (it) 2004-06-14
PL378418A1 (pl) 2006-04-03
CY1109051T1 (el) 2014-07-02
KR20050084052A (ko) 2005-08-26
ES2322455T3 (es) 2009-06-22
CA2507429C (en) 2012-09-04
WO2004054567A1 (en) 2004-07-01
PT1569635E (pt) 2009-05-11

Similar Documents

Publication Publication Date Title
JP6077857B2 (ja) β−ヒドロキシ−β−メチル酪酸塩（ＨＭＢ）の改善された投与方法
JP5690261B2 (ja) β−ヒドロキシ−β−メチル酪酸および少なくとも１つのアミノ酸を含む組成物および使用法
JPH07507569A (ja) ヒトの窒素保持の促進方法
JPH04507091A (ja) 体重減量医薬組成物
JP2005513107A (ja) （−）−ヒドロキシクエン酸、クロム、およびギムネマ酸を含有する組成物、および健常体重を促進する方法と関連する健康因子を改善する方法
TWI331920B (en) Unit dosage form for relieving or treating constipation in human patients
JP2004521127A (ja) 異常脂血症及び食事誘発性食後高血糖症のクロム／ビオチン療法
JPH09323927A (ja) 慢性閉塞性動脈硬化症の治療のためのカルニチン誘導体含有薬剤
US8435963B2 (en) Weight loss compositions and uses thereof
US7956091B2 (en) Use of carnitines for the prevention and/or treatment of disorders caused by the andropause
US7776913B2 (en) Carnitines for treating or preventing disorders caused by andropause
JP2020510607A (ja) 疾病治療用カプリン酸及びミリスチン酸組成物
US20180055848A1 (en) Combination of Albuterol and Caffeine as Synergistic Treatment for Obesity or Sarcopenia
JPH0657654B2 (ja) 患者の疲労減少用組成物
JPWO2008136173A1 (ja) スチルベン誘導体を有効成分とする脂肪細胞分化抑制剤
JPWO2007069744A1 (ja) メタボリックシンドローム予防・改善用組成物
US20230149330A1 (en) Sleep quality improver
Haslbeck et al. Diagnosis, treatment and follow-up of diabetic neuropathy
HK40083684A (en) Agent for improving quality of sleep
WO2025218622A1 (zh) 用于改善生殖健康的方法和组合物
JP2014051459A (ja) 脂質代謝促進剤
WO2022018705A1 (en) A pharmaceutical composition for treating cardiovascular and cerebrovascular disorders,diseases in pregnant women and improving exercise tolerance
EA049387B1 (ru) Фармацевтическая композиция, способ лечения хронической ишемической болезни сердца, или стабильной стенокардии напряжения, или атеросклероза переферических сосудов у человека, способ лечения острых нарушений мозгового кровообращения, способ профилактики и лечения таких заболеваний беременных женщин и развития плода во время беременности как преэклампсия беременных женщин, дистресс плода, задержка внутриутробного развития плода, способ повышения толерантности к физическим нагрузкам у человека
CN112641765A (zh) 丙泊酚的抗疲劳制药用途
JP2019214618A (ja) ウロプラキン発現促進剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100825

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110524

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110615

R150 Certificate of patent or registration of utility model

Ref document number: 4767542

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140624

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees